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Summary
Background  and  purpose:  Although  it  has  been  reported  that  matrix  metalloproteinases  (MMPs)
are associated  with  left  ventricular  (LV)  remodeling  in  patients  with  hypertrophic  cardiomyopa-
thy (HCM),  the  impact  of  plasma  MMP  levels  in  patients  with  HCM  is  somewhat  vague.
Methods and  subjects:  Plasma  levels  of  MMP-2,  MMP-9,  and  clinical/echocardiographic  ﬁndings
were evaluated  in  16  HCM  patients  with  preserved  LV  ejection  fraction  (deﬁned  as  LV  ejection
fraction more  than  50%)  caused  by  an  identical  frameshift  mutation  (S593fs:  a  one-base  deletion
of a  thymidine  at  nucleotide  11,645)  in  the  cardiac  myosin-binding  protein  C  gene.
Results:  MMP-2  levels  were  inversely  related  to  LV  ejection  fraction  (r2 =  −37,  p  =  0.01).  MMP-9
levels were  inversely  related  to  LV  end-diastolic  dimension  (r2 =  −0.24,  p  =  0.06)  and  posi-
tively related  to  the  maximum  LV  wall  thickness  (r2 =  0.25,  p  =  0.04).  During  follow-up  period  of
4.1 ±  1.2  years,  LV  ejection  fraction  decreased  from  68.5  ±  7.4%  to  64.9  ±  9%  (p  =  0.03).  Among
clinical, echocardiographic  ﬁndings  at  baseline  and  levels  of  biomarkers,  high  MMP-9  levels
were only  related  to  the  decrease  of  LV  ejection  fraction  from  baseline  to  follow-up  (r2 =  0.39,
p =  0.009).
Conclusions:  MMP-2  levels  are  related  to  reduced  LV  systolic  function  in  HCM  patients  with
preserved  LV  ejection  fraction  caused  by  an  identical  cardiac  myosin-binding  protein  C  gene
abnormality.  On  the  other  hand,  MMP-9  levels  are  associated  with  small  LV  size  and  the  degree
of LV  hypertrophy  and  related  to  the  deterioration  in  LV  systolic  function  during  follow-up.
These results  suggest  that  MMPs
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doi:10.1016/j.jjcc.2011.07.011 are  important  in  the  process  of  LV  remodeling  in  HCM.
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ntroduction
ypertrophic  cardiomyopathy  (HCM)  is  a  primary  myocar-
ial  disease  that  has  been  deﬁned  as  left  ventricular  (LV)
ypertrophy  in  the  absence  of  other  cardiovascular  diseases,
nd  is  caused  by  abnormalities  mainly  in  the  sarcomere  pro-
ein  genes  [1,2]. The  clinical  and  morphological  features  of
atients  with  HCM  are  diverse,  and  the  natural  history  varies
rom  an  asymptomatic  and  benign  clinical  course  to  heart
ailure,  stroke,  and  sudden  premature  death  [3,4].
LV  systolic  impairment  secondary  to  LV  remodeling  occurs
n  approximately  5—10%  of  adult  HCM  patients  (referred  to
s  dilated  HCM  or  end-stage  HCM)  and  is  associated  with
efractory  heart  failure  and  a  poor  prognosis  [5—8]. Great
nterest  has  been  paid  to  the  signiﬁcance  of  the  extracellu-
ar  matrix  in  LV  remodeling  in  various  cardiovascular  diseases
9—12]  including  patients  with  HCM  [13—16]. However,  the
esults  from  previous  reports  are  somewhat  disordered,
ecause  of  patient  selection  (including  LV  systolic  impair-
ent  or  not)  or  the  lack  of  information  on  gene  abnormality.
herefore,  this  study  aimed  (1)  to  elucidate  whether  plasma
evels  of  matrix  metalloproteinases  (MMPs)  were  related  to
V  remodeling  in  patients,  and  (2)  to  observe  whether  MMPs
evels  were  related  to  the  deterioration  in  LV  systolic  func-
ion  during  follow-up  in  HCM  patients  with  preserved  LV
jection  fraction  (LVEF)  caused  by  an  identical  sarcomere
utation.
ubjects and methods
ubjects  and  study  design
he  diagnosis  of  HCM  was  based  on  echocardiographic  con-
rmation  of  a  hypertrophied  left  ventricle  (maximum  wall
hickness  ≥15  mm)  in  the  absence  of  systemic  hyperten-
ion  or  other  cardiac  diseases  (such  as  aortic  stenosis  or
torage  disease)  that  could  produce  hypertrophy  of  such
agnitude  [1,2]. Genetic  analysis  was  performed  as  pre-
iously  reported  [17,18].  In  this  study,  we  retrospectively
elected  16  patients  with  the  same  frameshift  mutation  (a
593fs:  a  one-base  deletion  of  a  thymidine  at  nucleotide
1,645)  in  the  cardiac  myosin-binding  protein  C  gene.  Among
6  patients,  11  patients  were  included  in  our  previous  study
15]. The  interval  between  echocardiographic  evaluation
nd  taking  blood  samples  was  within  three  months  in  all
atients.  Biomarkers  were  measured  at  the  beginning  of  the
ollow-up  period  in  this  study.  Clinical  characteristics,  lab-
ratory  parameters  and  echocardiographic  ﬁndings  of  the
atients  were  determined  while  they  were  clinically  stable.
atients  with  LV  systolic  impairment  (LVEF  less  than  50%  at
aseline)  were  excluded  from  this  study.  Patients  with  renal
ysfunction  (estimated  glomerular  ﬁltration  rate  less  than
0%),  hepatic  disease,  respiratory  disease,  inﬂammatory  dis-
ase,  or  malignancy  were  excluded  because  such  conditions
ight  inﬂuence  collagen  metabolism.
The  Ethics  Committee  for  Medical  Research  at  our  insti-
ution  approved  the  study  protocol  and  all  patients  provided
ritten  informed  consent  to  participate.
P
p
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chocardiography
chocardiographic  images  were  acquired  using  a  digital
ltrasound  system  (Sequoia  512;  Acuson,  Mountain  View,
A,  USA).  The  dimensions  of  the  left  ventricle  and  the  left
trium  were  measured  and  the  magnitude  and  distribution
f  LV  hypertrophy  were  assessed  from  the  two-dimensional
mages  [3,19]. The  greatest  wall  thickness  measured  at  any
ite  in  the  left  ventricle  was  regarded  as  maximal  thickness.
he  intraventricular  pressure  gradient  was  also  measured
sing  continuous-wave  Doppler  under  basal  conditions  and
n  LV  outﬂow  tract  gradient  of  ≥30  mmHg  was  considered
igniﬁcant.  LVEF  was  calculated  by  the  modiﬁed  Simpson’s
ethod.
iomarker  measurements
eripheral  venous  blood  samples  were  collected  from  the
ntecubital  veins  of  patients  after  they  were  supine  for
5  min  without  drug  discontinuation.  Plasma  was  separated
y  centrifugation  at  3500  ×  g  for  15  min.  Aliquots  were
tored  at  −80 ◦C.  We  measured  levels  of  MMP-2,  MMP-9,
issue  inhibitor  of  metalloproteinase  (TIMP)-1,  and  procol-
agen  type  III  aminoterminal  peptide  (PIIINP)  using  one-step
andwich  enzyme  immunoassay  kits  (Daiichi  Fine  Chemi-
al  Co.,  Toyama,  Japan).  These  kits  contained  monoclonal
ntibodies  speciﬁc  for  MMP-2  (clone  42-5D11,  IgG1  isotype)
hat  speciﬁcally  reacts  with  precursor  and  active  forms  of
uman  MMP-2;  MMP-9  (clone  56-2A4,  IgG1  isotype)  that
peciﬁcally  reacts  with  precursor  (92  kDa)  and  intermedi-
te  (83  kDa)  forms  of  human  MMP-9,  but  not  with  active
7-kDa  human  MMP-9,  and  to  TIMP-1  (clone  147-6D11,  IgG1
sotype)  that  speciﬁcally  reacts  with  human  TIMP-1.  PIIIPN
evels  were  measured  using  commercial  radioimmunoas-
ay  kits  (CIS  Bio  International,  Bagnois-sur-Ceze,  France).
lasma  B-type  natriuretic  peptide  (BNP)  levels  were  also
easured  using  an  enzyme  immunoassay  (Tosoh  II;  Tosoh,
okyo,  Japan).
tatistical  analysis
ata  are  presented  as  means  ±  standard  deviation  (SD).
orrelations  between  laboratory  ﬁndings  and  continuous
ariables  were  evaluated  using  linear  regression  analysis.
ariables  between  the  two  groups  were  compared  using  the
ilcoxon  rank-sum  test.  Nominal  variables  expressed  as  pro-
ortions  were  compared  using  the  2 test  or  Fisher’s  exact
est.  A  p-value  of  <0.05  was  considered  statistically  signiﬁ-
ant.  Data  were  statistically  analysed  using  JMP  version  8.0
oftware  (SAS  Institute  Inc.,  Cary,  NC,  USA).
esults
atient  characteristicsatient  characteristics  are  shown  in  Table  1.  Almost  all
atients  were  asymptomatic  or  had  mild  symptoms  (New
ork  Heart  Association  class  I/II).
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Table  1  Baseline  patient  characteristics  and  echocardio-
graphic  ﬁndings.
Patient  characteristics
Male  gender,  n  (%)  9  (63)
Age, years  52.7  ±  11.4
NYHA  class  I/II,  n  (%) 15  (94)
Atrial ﬁbrillation,  n  (%) 3  (19)
Ventricular  tachycardia,  n  (%) 3  (19)
Medication
Beta blocker,  n  (%)  8  (50)
Calcium  antagonist,  n  (%)  3  (19)
ACEI/ARB,  n  (%)  2  (13)
Amiodarone,  n  (%)  1  (6)
Echocardiographic  ﬁndings
LV  end-diastolic  dimension  (mm) 42.5  ±  4.9
LV end-systolic  dimension  (mm)  25.6  ±  4.2
Intraventricular  septal  thickness  (mm)  19.4  ±  4.2
Posterior  wall  thickness  (mm)  11  ±  1.9
Maximum  LV  wall  thickness  (mm) 22.3  ±  4.7
Left atrial  dimension  (mm)  43.1  ±  5.9
LVEF (%) 68.5  ±  7.4
LV outﬂow  gradient,  n  (%) 1  (6)
NYHA, New York Heart Association; ACEI, angiotensin-converting
Table  3  Comparison  between  parameters  and  decrease  in
LVEF from  baseline  to  follow-up.
r2 p-Value
Age  −0.05  0.39
Gender  —  0.72
Atrial ﬁbrillation  —  0.5
Beta-blocker  use  —  0.51
Echocardiographic  ﬁndings  at  baseline
LV  end-diastolic  dimension 0.003  0.83
LV end-systolic  dimension 0.03  0.55
Intraventricular  septal  thickness 0.09  0.25
Posterior  wall  thickness  0.24  0.05
Maximum  LV  wall  thickness  0.007  0.76
Left atrial  dimension 0.05  0.43
LV ejection  fraction  0.08  0.28
Biomarkers
MMP-2 −0.09  0.27
MMP-9 0.39  0.009
TIMP-1 0.01  0.18
PIIIPN −0.09  0.28
BNP −0.07  0.32
LV, left ventricular; EF, ejection fraction; MMP, matrix metallo-
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ventricular; EF, ejection fraction.
Plasma  levels  of  biomarkers  and  baseline
echocardiographic  ﬁndings
The  levels  of  MMP-2,  MMP-9,  TIMP-1,  and  PIIIPN  were  934.5  ±
140.7  ng/mL,  335.9  ±  185.4  ng/mL,  177.7  ±  29.1  ng/mL,
and  0.6  ±  0.09  U/mL,  respectively.  Plasma  BNP  levels  were
180.6  ±  130.7  pg/mL.
Echocardiographic  ﬁndings  are  also  presented  in  Table  1.
We  observed  LV  outﬂow  tract  obstruction  in  one.  No  patient
showed  an  apical  HCM  phenotype.
The  relationship  between  levels  of  MMPs  and  echocar-
diographic  ﬁndings  is  shown  in  Table  2.  The  levels  of  MMP-2
were  inversely  related  to  LVEF.  On  the  other  hand,  MMP-9
levels  were  positively  related  to  maximum  LV  wall  thickness
and  negative  interaction  was  found  between  MMP-9  levels
and  LV  dilatation.  Levels  of  PIIIPN,  TIMP-1,  and  BNP  were
not  related  to  any  echocardiographic  parameters.
b
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Table  2  Comparison  of  MMP  levels  and  baseline  echocardiograph
MMP-2
r2
LV  end-diastolic  dimension  0.17  
LV end-systolic  dimension  0.13  
Intraventricular  septal  thickness  −0.09  
Posterior wall  thickness  −0.11  
Maximum LV  wall  thickness  0.09  
Left atrial  dimension  0.11  
LVEF −0.37  
MMP, matrix metalloproteinase; LV, left ventricular; EF, ejection fractio
The italics show the statistically signiﬁcant parameters.proteinase; TIMP, tissue inhibitor of metalloproteinase; PIIIPN,
procollagen type III aminoterminal peptide; BNP, B-type natri-
uretic peptide.
hange  in  LV  systolic  function  and  plasma  levels  of
iomarkers
ean  interval  of  echocardiography  between  baseline
nd  follow-up  was  4.1  ±  1.2  years.  LVEF  decreased  from
8.5  ±  7.4%  to  64.9  ±  9.0%  (p  =  0.03).  LVEF  decreased  more
han  5%  in  six  patients.  One  patient  evolved  into  LV  systolic
mpairment  (LVEF  less  than  50%).  MMP-9  levels  in  those  six
atients  tended  to  be  higher  than  those  in  patients  with-
ut  decrease  of  LVEF  (442  ±  235  ng/mL  vs.  272  ±121  ng/mL,
 =  0.09).  On  the  other  hand,  there  was  no  difference
etween  six  patients  and  the  others  in  the  basic  charac-
eristics,  such  as  the  incidence  of  atrial  ﬁbrillation  and
eta-blocker  use,  and  echocardiographic  ﬁndings  at  base-
ine.  Decrease  in  LVEF  from  baseline  to  follow-up  was
ompared  to  age,  baseline  echocardiographic  ﬁndings,  and
he  plasma  levels  of  biomarkers  (Table  3).  High  MMP-9  levels
ic  ﬁndings.
MMP-9
p-Value  r2 p-Value
0.1  −0.24  0.06
0.16  −0.22  0.07
0.25  0.13  0.16
0.22  0.2  0.08
0.25  0.25  0.04
0.21  −0.12  0.5
0.01  0.08  0.3
n.
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ere  only  related  to  the  decrease  in  LVEF  from  baseline  to
ollow-up.
On  the  other  hand,  LV  end-diastolic  dimension  did  not
igniﬁcantly  change  during  follow-up  (from  42.5  ±  4.9  mm  to
2.7  ±  4.3  mm,  p  =  0.8)  although  LV  end-diastolic  dimension
ncreased  more  than  3  mm  in  three  patients.  The  levels  of
MP-2  and  MMP-9  were  not  related  to  the  change  in  LV  end-
iastolic  dimension.
iscussion
he  main  ﬁndings  of  this  study  are  that  (1)  plasma  MMP-
 levels  are  inversely  related  to  the  LV  systolic  function,
nd  (2)  plasma  MMP-9  levels  are  inversely  related  to  LV  size
nd  positively  related  to  the  degree  of  LV  hypertrophy  in
CM  patients  with  preserved  LVEF  caused  by  the  identical
isease-causing  mutation.  Moreover,  high  MMP-9  levels  were
elated  to  the  deterioration  in  LV  systolic  function  during
ollow-up.  To  our  knowledge,  this  is  the  ﬁrst  report  that  MMP
evels  are  related  to  the  decrease  in  LV  systolic  function
uring  follow-up  in  patients  with  HCM.
xtracellular  collagen  matrix  regulation  and  LV
emodeling  in  HCM
mpaired  collagenolysis  and  collagen  deposition  have  been
dentiﬁed  in  patients  with  HCM  and  the  signiﬁcance  of  MMP-2
gelatinase  A)  and  MMP-9  (gelatinase  B)  has  been  stud-
ed  in  patients  with  non-genotyped  HCM  [14—16]. However,
he  relationship  between  MMPs  and  LV  remodeling  in  HCM
emains  obscure.  Our  previous  study  and  that  of  other  inves-
igators  including  signiﬁcant  numbers  of  patients  with  LV
ystolic  impairment  have  found  that  high  plasma  MMP-2
evels  are  associated  with  LV  dilation  and  deteriorated  LV
ystolic  function  [14,15].  On  the  other  hand,  Roldán  and  col-
eagues  studied  the  relationship  between  the  levels  of  MMPs
nd  echocardiographic/cardiac  magnetic  resonance  ﬁndings
nd  reported  that  the  MMP-2  levels  were  negatively  related
o  LV  dimension  [16]. This  difference  in  the  previous  studies
ay  be  caused  by  patient  selection  (including  patients  with
V  systolic  impairment  or  not)  and  the  lack  of  genetic  infor-
ation.  Therefore,  we  studied  the  association  between  LV
emodeling  and  MMP  levels  in  HCM  patients  with  preserved
VEF  caused  by  an  identical  disease-causing  mutation.  We
ound  that  plasma  MMP-2  levels  were  related  to  the  deteri-
ration  in  LV  systolic  function,  and  that  plasma  MMP-9  levels
ere  related  to  small  LV  size  and  the  degree  of  LV  hypertro-
hy  in  HCM  patients  with  preserved  LVEF.  An  experimental
tudy  [20]  showed  that  MMP-2  remains  inactive  during  hyper-
rophy  and  becomes  activated  at  the  stage  of  LV  dilation  and
ystolic  impairment.  In  addition,  Ahmed  and  colleagues  [21]
eported  that  MMP-2  levels  are  decreased  and  MMP-9  levels
re  increased  in  patients  with  hypertension  and  LV  hyper-
rophy,  respectively.  Those  ﬁndings  were  in  agreement  with
hat  of  our  study.  Therefore,  we  believe  that  MMP-9  and
MP-2  regulate  alternatively  in  extracellular  matrix  regula-
ion  at  different  stages  (from  LV  hypertrophy  to  LV  systolic
mpairment)  during  lifelong  LV  remodeling  in  patients  with
CM.  Moreover,  high  MMP-9  levels  at  baseline  were  related
o  deterioration  in  LV  systolic  function  during  follow-up  in
his  study.  The  precise  reason  why  high  MMP-9  levels  wereH.  Kitaoka  et  al.
elated  to  smaller  LV  size  and  thicker  LV  wall  thickness  at
aseline  and  those  were  associated  with  deterioration  in  LV
ystolic  function  during  follow-up,  is  unclear.  We  speculate
hat  high  MMP-9  levels  may  reﬂect  the  intense  extracellu-
ar  matrix  turnover,  not  protect  for  LV  hypertrophy,  and  this
xcessive  activation  of  MMP-9  may  relate  to  LV  remodeling  in
uture.  In  fact,  high  MMP-9  levels  have  been  reported  to  be
orrelated  with  LV  dysfunction  and  remodeling  after  myocar-
ial  infarction  [12]. Furthermore,  greater  LV  wall  thickness
s  a  risk  factor  for  deterioration  of  LV  systolic  function  in
atients  with  HCM  [22]. Therefore,  the  activation  of  MMP-9
inked  to  LV  wall  thickness  may  be  a  new  predictive  marker
f  LV  remodeling  in  patients  with  HCM.
imitations
everal  limitations  are  associated  with  this  study.  First,
he  study  population  was  small.  Although  further  informa-
ion  about  the  roles  of  MMP-2  and  MMP-9  should  have  been
btained  by  serial  measurements,  we  could  not  measure  the
evels  of  biomarkers  at  several  points  because  of  a  retro-
pective  study  design.  In  addition,  we  obtained  no  control
ata.  Second,  we  have  no  direct  data  of  pathological  ﬁndings
o  establish  that  patients  speciﬁcally  had  collagen  matrix
lterations  in  cardiac  extracellular  matrix.  In  addition,  it
s  unresolved  whether  plasma  levels  of  biomarkers  reﬂect
he  activity  in  the  heart.  However,  clinical  evidence  has
een  constructed  that  plasma  biomarkers  of  extracellular
ollagen  matrix  turnover  are  useful  in  assessing  the  alter-
tion  of  the  collagen  matrix  in  cardiac  disease  [23]. Although
MP-9  levels  were  signiﬁcantly  related  to  decrease  in  LVEF,
hey  were  not  related  to  LV  dilatation  during  follow-up.  This
esult  may  be  caused  by  the  ﬁndings  that  LV  dilatation  in
CM  is  relatively  mild  compared  to  myocardial  infarction  or
ilated  cardiomyopathy.  Finally,  this  study  was  conducted  in
atients  with  HCM  caused  by  an  identical  cardiac  myosin-
inding  protein  C  gene  abnormality,  because  other  gene
utations  are  relatively  few  in  our  patient  population.
herefore,  it  is  unclear  whether  the  results  of  this  study
epend  on  this  speciﬁc  gene  abnormality.  Further  analysis  is
arranted  to  deﬁne  the  association  between  LV  remodeling
nd  extracellular  collagen  matrix  regulation  in  patients  with
CM.
onclusions
lasma  MMP-2  levels  are  related  to  reduced  LV  systolic  func-
ion  in  HCM  patients  with  preserved  LVEF.  On  the  other
and,  MMP-9  levels  are  associated  with  small  LV  size  and
he  degree  of  LV  hypertrophy  at  baseline  and  related  to  the
eterioration  in  LV  systolic  function  during  follow-up.  The
esults  of  the  present  study  suggest  that  MMPs  play  an  impor-
ant  role  in  LV  remodeling  in  such  patients  and  thus  novel
herapeutic  strategies  based  on  this  perspective  should  be
onsidered  to  improve  patient  prognosis.
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